(1) Department of Nuclear Medicine, Medical Physics, Radiology, Neuroradiology, PET/CT Centre, ‘Santa Maria della Misericordia’ Hospital, Via Tre Martiri 140, 45100 Rovigo, Italy
(2) Department of Medical Physics, ‘Santa Maria della Misericordia’ Hospital, Rovigo, Italy
(3) Department of Oncology, ‘Santa Maria della Misericordia’ Hospital, Rovigo, Italy
(4) Current address: Nuclear Medicine and Radiology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
Corresponding author Email: email@example.com
Gastrointestinal stromal tumours (GISTs) represent a major fraction of gastrointestinal sarcomas, frequently showing c-kit exon 11 mutations and associated with a good response to imatinib mesylate. Secondary resistance to imatinib has also been reported during therapy; therefore, clinicians need non-invasive tools for early assessment of treatment response due to traditional morphologic criteria [X-rays and computerized tomography (CT)] being unsuccessful.
We report upon a patient with GIST with exon 11 mutation showing excellent response to imatinib mesylate, only a few days after initiation of the therapy and persisting for 18 months of follow-up. Here we also provide a short review of the recent literature on this topic.
There is evidence that F-FDG PET18 and PET/CT could be used to optimally monitor c-kit inhibitor therapy in GISTs, detecting early responders, non-respon-ders and secondary resistance, there by allowing better patient management.